Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    Pilot Study of Redirected Autologous Tcells Engineered to Contain Anti-CD19
Show Display Options
Rank Status Study
1 Active, not recruiting CD19 Redirected Autologous T Cells for Hodgkin Lymphoma
Condition: Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis
Intervention: Biological: RNA anti-CD19 CAR T cells
2 Completed Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy
Conditions: Hematopoietic/Lymphoid Cancer;   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Other: laboratory biomarker analysis;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Biological: anti-CD19-CAR retroviral vector-transduced autologous T cells;   Biological: genetically engineered lymphocyte therapy
3 Active, not recruiting CART-19 for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: CART-19 T cells
4 Recruiting Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
Conditions: Acute Lymphocytic Leukemia;   Diffuse Large Cell Lymphoma
Intervention: Biological: huCART19
5 Recruiting Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Biological: CD19 RNA redirected autologous T-cells (RNA CART19 cells)

Indicates status has not been verified in more than two years